Glucotrace (Fludeoxyglucose (18f))

Glucotrace is indicated for several PET imaging applications that require assessment of cellular glucose metabolism. It helps clinicians evaluate disease presence and progression in specific organ systems.

• Oncologic PET imaging for detection, staging, and monitoring of malignant tumors.
• Cardiac PET imaging to assess myocardial viability and perfusion.
• Neurologic PET imaging for epilepsy, dementia, and movement disorders.
• Research studies investigating metabolic pathways in vivo.
• Whole‑body PET scans for comprehensive disease assessment.

Adverse reactions to Glucotrace are generally mild and related to the radiopharmaceutical nature of the product. Serious events are rare but may occur.

Common

• Transient flushing or warmth sensation at the injection site.
• Mild nausea or vomiting.
• Temporary headache.
• Short‑lasting dizziness.
• Mild allergic skin reactions (e.g., erythema).

Serious

• Severe hypersensitivity or anaphylaxis.
• Significant radiation‑induced tissue injury (extremely rare).
• Prolonged hypotension.
• Acute renal impairment in patients with pre‑existing kidney disease.

Glucotrace should be used with careful consideration of patient‑specific factors and procedural requirements. The following precautions are recommended:

• Verify pregnancy status; avoid use in pregnant women unless the diagnostic benefit outweighs potential fetal radiation exposure.
• Assess renal function before administration, especially in patients with known kidney disease.
• Ensure proper hydration to facilitate radiotracer clearance.
• Observe radiation safety protocols for staff and surrounding individuals.
• Review patient history for prior allergic reactions to radiopharmaceuticals.
• Adjust dosage for pediatric patients according to weight‑based guidelines.
• Document and monitor any adverse events promptly.

Glucotrace may interact with other agents that affect glucose metabolism or radiation exposure. Consider the following:

Avoid

• High‑dose glucose or insulin therapy immediately before the scan, which can alter tracer uptake.
• Concurrent administration of other radiopharmaceuticals that may confound PET image interpretation.

Use with caution

• Medications that modify blood glucose levels (e.g., metformin, sulfonylureas) – consider temporary discontinuation per protocol.
• Contrast agents used in CT components of PET/CT studies – assess cumulative radiation dose.
• Chemotherapeutic agents that affect tumor metabolism – timing of imaging may need adjustment.
• Beta‑blockers or other cardiovascular drugs that could influence myocardial uptake.
• Any investigational drugs in clinical trials – coordinate with study investigators.